All analyses
AI analysis

Asiri Hospitals Ltd.: research report

Fairly valuedbullishAug 7, 2026

Asiri delivered a 14.3% net margin in its structurally weakest quarter while the share fell 24% over three months.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • Valuation screens cheap: P/E 8.18 versus the healthcare sector median 13.14.
  • Operationally resilient: latest quarter net margin was 14.3% and net profit rose 11.1% year-on-year despite a 5.1% drop in operating profit.
  • De-rated price: the 3‑month fall of 24.3% leaves P/B at 1.56 versus the sector median 2.33.

Against this. Balance-sheet headroom is tight, with interest cover at 2.19x.

Operating margin
20.3%sector 14.5%
from 23.4% a year earlier
Net margin
14.3%sector 10.9%
from 14.1% a year earlier, revenue +9.1%
Return on equity
11.7%sector 11.2%
full year to Mar 31, 2026
P/E
6.4sector 10.8
earnings Rs 4.39 per share
P/B
1.25sector 1.41
book Rs 22.40 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Jun 30, 2026. The report below was written on Aug 7, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Hospitals Ltd. is Sri Lanka’s largest private hospital and diagnostics network, operating seven accredited hospitals and an extensive labs footprint under the Asiri Health brand. The latest quarter reads better than it looks at first glance: it came in the calendar June period, which is structurally the weakest quarter for gross margin, yet profitability at the group level held up well and improved year-on-year.

Price performance

As at 2026-08-07 the share closed at LKR 35.00. It fell 24.3% over three months versus the ASPI’s -7.1%, while over six months it rose 5.8% against the index’s -10.6%. The price sits 24.3% below its 52‑week high, in the lower third of the range. Volatility is roughly in line with the stock’s own one‑year norm and volumes are slightly lighter than their 60‑day average.

Valuation

The stock trades on a P/E of 8.18 against a healthcare sector median of 13.14, and a P/B of 1.56 versus a sector median 2.33. On the latest full year, ROE was 8.4%. Dividend visibility is limited: a LKR 1.5 per share payout is recorded for FY2025, with no dividend recorded for FY2023 and FY2024.

News and sentiment

Coverage has been quiet: zero material articles in the last 90 days, consistent with the data-flagged tension that the price moved without fresh company news. The last confirmed corporate action was a first interim dividend (ex 2024-09-26) for FY2025. An enforcement-action notice dated 2026-03-13 is the most recent notable filing on record, but it sits well outside the current sentiment window.

Financials

June-quarter margins held firm year-on-year despite the season: gross margin was 51.0% versus 50.9% a year ago, operating margin was 20.3% versus 23.4%, and net margin was 14.3% versus 14.1%. Revenue and net profit both grew year-on-year, while operating profit declined, indicating the below-the-line drag eased compared with the same quarter last year. Within its own history, June is normally the weakest quarter for gross margin, which frames this print as robust rather than soft.

Risks

Funding and liquidity are the lead risks. At FY2025, interest cover was 2.19x and the current ratio 0.49, leaving limited cushion if costs or collections wobble. Cash conversion was 0.59x, so a fair slice of operating profit did not arrive as cash. Gearing stood at 76.9% of owners’ equity, with total debt of LKR 15.12 billion. Minority interests are meaningful at 10.0% of group net profit, so group profit and earnings to ASIR shareholders are not the same pot.

Outlook

Next figures are due for the quarter to 2026-09-30, expected between 2026-10-28 and 2027-01-26. As at 2026-08-07, the key watchpoint is whether the easing in market interest rates feeds through to a lower finance charge, given the tight interest cover. With news flow sparse, the next filing is the event most likely to resolve the recent price-fundamentals disconnect.

About this report. Generated on Aug 7, 2026 from market data up to Aug 7, 2026, 0 material news articles over 90 days and financials to Jun 30, 2026. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports